$2.36
+0.00 (+0.00%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AYTU is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 observational
Held by 3 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC) · FINRA short interest 12.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0NCT02839447observationalStatic Oxidation Reduction Potential (sORP) between Normal and Abnormal semen samples | — | Withdrawnsponsor's stated reason: Study halted prematurely, prior to enrollment of first participant | Diagnostic test: Diagnostic | Male Infertility | 0 | Jan 2026 | 2024-03-08 |
| ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity DisorderNCT07169162Attention-deficit/hyperactivity disorder Rating Scale-IV Preschool Version Total ScoreRandomized · Quadruple-masked · Treatment | Phase 4 | Withdrawnsponsor's stated reason: Enrollment never started | Drug: ADZENYS XR-ODT, Placebo Oral Tablet | Attention Deficit Hyperactivity Disorder | 0 | 2025-09-05actual | 2025-10-03 |
| Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.NCT05463679Time to intervention for an arterial event (rupture, dissection, pseudoaneurysm, carotid-cavernous sinus fistula, or aneurysm, fatal or not) or mortality attributable to an arterial event.Randomized · Triple-masked · Prevention | Phase 3 | Suspendedsponsor's stated reason: Indefinite hold by company | Drug: Enzastaurin, Placebo | Vascular Ehlers-Danlos Syndrome | 260 | Jun 2025 | 2024-03-08 |
| Respiratory COVID-19: A Randomized, Sham-Controlled StudyNCT05166915Change in viral load in endotracheal tube aspiratesRandomized · Double-masked · Treatment | Not applicable | Withdrawnsponsor's stated reason: Indefinite hold by Company. | Device: UVA Light Emitting Catheter, Sham Control Catheter | COVID-19 Pneumonia, Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Respiratory Infection | 0 | Dec 2022 | 2022-10-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19